The 'nephrotoxins' were stopped: what is in a name and its impact on kidney and cardiac health?
「nephrotoxins」被停用了:名稱的意義及其對腎臟與心臟健康的影響
Intern Med J 2025-04-22
Induction of proximal tubular proliferation and lengthening in response to sodium glucose linked cotransporter-2 inhibition in experimental rats.
SGLT2 抑制劑誘導實驗鼠近端腎小管增生與延長的研究
J Diabetes Investig 2025-04-22
The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS).
左心室射出分率在心衰竭診斷與治療中的應用——歐洲心衰竭協會(HFA)、美國心衰竭學會(HFSA)及日本心衰竭學會(JHFS)臨床共識聲明
Eur J Heart Fail 2025-04-22
Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis.
接受anthracycline治療之癌症患者使用SGLT2抑制劑對心血管結局的影響:系統性回顧與統合分析
Ecancermedicalscience 2025-04-22
Cardiorenal benefits of SGLT2 inhibitors in patients with chronic kidney disease and concomitant hypertension.
SGLT2 抑制劑在合併高血壓的慢性腎臟病患者中的心腎益處
Cardiorenal Med 2025-04-21
Use of SGLT2 Inhibitors Versus DPP-4 Inhibitors and Age-Related Macular Degeneration in Patients WithType 2 Diabetes: A Multinational Cohort Study.
SGLT2 抑制劑與 DPP-4 抑制劑的使用及其對第二型糖尿病患者年齡相關性黃斑部病變的影響:一項多國隊列研究
Invest Ophthalmol Vis Sci 2025-04-21
The SGLT2 inhibitor canagliflozin attenuates mitochondrial oxidative stress and alterations of calcium handling induced by high glucose in human cardiac fibroblasts.
SGLT2 抑制劑 canagliflozin 可減輕高血糖誘發之人類心臟纖維母細胞的粒線體氧化壓力及鈣離子調控異常。
Cell Cycle 2025-04-21